Active	Status	Sponsor type	Region	Phase	Filter
5 Active 3 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Thaci, Diamant
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis	Recruiting	3	1300	Europe, Canada, Japan, US, RoW	TAK-279	Takeda	Plaque Psoriasis	05/26	05/26
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata	Recruiting	3	595	Europe, Canada, Japan, US, RoW	Baricitinib, LY3009104, Placebo	Eli Lilly and Company	Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical	09/24	08/29
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment	Active, not recruiting	3	693	Europe, Canada, Japan, US, RoW	TAK-279, Placebo, Apremilast	Takeda	Plaque Psoriasis	08/25	04/26
OREA, NCT05131373: Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris	Completed	1	38	Europe	ORG101 - Experimental 1, ORG101PL - Placebo 1	Sanofi Pasteur, a Sanofi Company	Acne Vulgaris, Acne	11/23	11/23
TARGET-DERM, NCT03661866: A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC	Recruiting	N/A	15000	Europe, Canada, US		Target PharmaSolutions, Inc.	Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria	12/50	12/50